The KDM7A Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HeLa cell line. This product provides a loss-of-function model for studying KDM7A-dependent biological processes. The polyclonal nature, generated without single-cell cloning, avoids clonal selection biases and allows assessment of gene disruption effects across a heterogeneous cellular pool, maintaining the endogenous regulatory context of this widely utilized human cancer cell line.
HeLa cells, the host for this knockout model, originate from a human cervical adenocarcinoma and exhibit hallmark features such as integrated HPV18 DNA, loss of p53 function, and a highly proliferative, aneuploid karyotype. These characteristics make HeLa one of the most extensively used epithelial cell lines in cancer research, particularly for exploring mechanisms of genomic instability, oncogenic signaling, and epigenetic reprogramming. The cell line’s aberrant chromatin state provides a sensitized background for examining chromatin-modifying enzymes like KDM7A.
KDM7A encodes a JmjC domain-containing histone demethylase that specifically removes methyl groups from H3K9me2 and H3K27me2, functioning as a transcriptional coregulator. Its activity is shaped by upstream Wnt/??-catenin signaling and pluripotency factors OCT4 and SOX2. KDM7A interacts with ARID5B, PHF2, HP1??, and RNA polymerase II to modulate chromatin and activates neural genes such as NEUROG1 and DCX while repressing developmental inhibitors. This integration links chromatin remodeling to cell fate decisions.
Disruption of KDM7A in HeLa cells is particularly informative given the line’s dysregulated epigenome, p53 deficiency, and aneuploidy. KDM7A has been associated with acute myeloid leukemia, myelodysplastic syndromes, glioblastoma, and neurodevelopmental disorders. In this context, the knockout model allows researchers to investigate how loss of KDM7A affects histone methylation dynamics, gene expression, and cellular phenotypes such as proliferation and differentiation, thereby illuminating epigenetic mechanisms in cancer.
Researchers can employ this knockout model in diverse applications. Western blotting and RT-qPCR validate KDM7A disruption, while global analysis of H3K9me2/H3K27me2 levels assesses direct biochemical effects. Chromatin immunoprecipitation (ChIP-qPCR) and immunofluorescence examine locus-specific and spatial histone modifications, and RNA-seq profiles transcriptional changes. Proliferation and differentiation assays evaluate functional consequences. The cells are suited for epigenetic regulation studies, histone demethylase characterization, cancer epigenetics, neuronal differentiation, and inhibitor screening. For further information or technical support, please contact Ascent Research.
